Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Cognitive decline can occur before chemotherapy treatment, as well as after

21.06.2004

In a series of studies in breast cancer patients, researchers at The University of Texas M. D. Anderson Cancer Center have confirmed the presence of "chemobrain" after chemotherapy treatment - but they also discovered that a significant portion of patients have cognitive declines even before chemotherapy.

The studies, the latest of which is reported June 21 in the online edition of the journal Cancer, are the first to document such pretreatment losses in patients with non-metastatic breast cancer. Researchers suggest that problems associated mostly with learning and memory likely arise due to the disease process itself, lending validation to patients who have noticed the problems, but have a hard time convincing their physicians.

"These losses are not due to emotions or anxiety, and patients are grateful when it is recognized," says Christina Meyers, Ph.D., professor of neuropsychology in the Department of Neuro-Oncology, who has lead the series of studies. "We want them to know that we are trying to understand why this happens and that there are a wide variety of therapies available to help them."

The research team cannot yet pinpoint a reason as to why the declines occur, but say factors such as a systemic immune inflammatory reaction produced during illness may play a role, as may a person’s hormonal profile and unique genetic susceptibilities.

They add that the problem is likely not related to gender: Meyers has also found similar cognitive declines before chemotherapy treatment in men with non-small cell lung cancer.

"There is a subset of patients with any kind of cancer who may have cognitive impairment related to having the cancer, and there may be a number of different biological reasons as to why this happens," says first author Jeffrey Wefel, Ph.D., a member of Meyers’ neuropsychology group. "Most cancer treatments also will cause a decline in cognition in a vulnerable subset of patients."

All studies of "chemobrain" - cognitive decline due to chemotherapy - have measured brain functioning only after treatment. In this series of studies, the researchers looked at data from three separate prospective clinical trials conducted at M. D. Anderson that examined cognitive functioning before patients with non-metastatic breast cancer were treated with either tamoxifen or chemotherapy. In each investigation, patients received a comprehensive neuropsychologic evaluation before treatment.

The first report, published in Cancer June 1, looked at one of the groups, composed of 18 patients who were to receive chemotherapy. The researchers found that before treatment, 33 percent of these patients showed cognitive impairments when tested, based on the expected scores they should have received given their ages, education, employment history and associated variables. After treatment with chemotherapy, 61 percent of this group demonstrated "chemobrain" declines in memory and learning.

Not every woman with early declines showed further declines after treatment, Meyers noted. "If they had a problem before chemotherapy, treatment did not necessarily provide an additional risk to declining further," she says.

One year after treatment, 50 percent of patients with "chemobrain" improved, the researchers found.

Studies on the other two cohort groups, one of which is near submission, showed similar results, Meyers says.

The study just reported in Cancer looked specifically at cognitive decline before treatment in all three cohorts, which totaled 84 patients. It found that, over all the groups, 35 percent (29 patients) exhibited impairments in verbal learning and memory functions compared to what was considered normal for these patients.

Although they do not know why the declines occurred, they noted "several provocative trends." Patients who appeared to have a greater risk of impairment either underwent more invasive surgery (lumpectomy or mastectomy), were postmenopausal, or had not previously used hormone replacement therapy. "Hormonal status may reduce a cognitive reserve, which may be associated with greater risk for suffering from adverse symptoms but we really don’t know," says Meyers.

She says causes of cognitive decline in cancer development could be due to the "soil" - host-related factors - or the "seed" - disease-related factors, or an interplay between both. Soil can include genetic differences, immune reactivity, nutritional factors, and hormonal status. Seed factors include tumor gene mutations, and an inflammatory or autoimmune reaction provoked by the cancer.

The researchers are continuing to investigate the roots of cognitive decline unrelated to treatment. Wefel says that if additional studies continue to show an association between cancer processes and mental functioning, patients may best be served by having cognitive tests as soon as cancer is diagnosed, as well as after treatment. "We have a whole platter of treatments to choose from that can help patients," Meyers says, which ranges from medications to accepted alternative therapies.

Stephanie Dedeaux | EurekAlert!
Further information:
http://www.utexas.edu

More articles from Studies and Analyses:

nachricht Multi-year study finds 'hotspots' of ammonia over world's major agricultural areas
17.03.2017 | University of Maryland

nachricht Diabetes Drug May Improve Bone Fat-induced Defects of Fracture Healing
17.03.2017 | Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>